Teva Pharmaceutical Industries Limited announced that the U.S. Food and Drug Administration approved two products for adolescent and adult patients with asthma. These products, AirDuoTM RespiClick® (fluticasone propionate and salmeterol inhalation powder) and ArmonAirTM RespiClick® (fluticasone propionate inhalation powder), include medication delivered via Teva’s RespiClick® breath-activated, multi-dose dry powder inhaler (MDPI) which is used with other approved medicines in Teva’s respiratory product portfolio. AirDuoTM RespiClick® is a fixed dose combination product containing the same active ingredients as Advair®. AirDuo™ RespiClick® is a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) indicated for the treatment of asthma in patients aged 12 years and older. ArmonAirTM RespiClick® is an inhaled corticosteroid (ICS) containing the same active ingredient as Flovent®, and is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years and older. AirDuo™ RespiClick® and ArmonAir™ RespiClick® are expected to become available to patients in the U.S., by prescription, later this year. Both products have been approved in three strengths. The approved strengths of AirDuo™ RespiClick® are: 55/14 mcg, 113/14 mcg and 232/14 mcg administered as one inhalation twice daily. The approved strengths of ArmonAir™ RespiClick® are: 55 mcg, 113 mcg, and 232 mcg administered as one inhalation twice daily.